GLOBAL INTERNATIONAL JOURNAL OF INNOVATIVE RESEARCH

https://global-us.mellbaou.com/

Open Access

Cite this article: Anurogo, D., Ginting, K. H., Damayanti, D. A. T., Mahmudah, S., & Handoyo, H. R. (2024). The Development of Novel Therapeutics for Antibiotic-Resistant Bacteria. Global International Journal of Innovative Research, 2(8). Retrieved from https://global-us.mellbaou.com/index.php/global/article/view/274

Keywords: Antibiotic Resistance, Novel Therapeutics, Bacteriophages, Antimicrobial Peptides, CRISPR-Cas Systems

Author for correspondence:
Dito Anurogo
E-mail: dito.anurogo@med.unismuh.ac.id

Published by:

GLOBAL SOCIETY PUBLISHING

The Development of Novel Therapeutics for Antibiotic-Resistant Bacteria

[1]Dito Anurogo, [2]Kevin Hizkya Ginting, [3]Dewa Ayu Trisna Damayanti, [4]Siti Mahmudah, [5]Henry Ricardo Handoyo

[1]Universitas Muhammadiyah Makassar, [2]Universitas HKBP Nommensen Medan, [3]Universitas Udayana, [4]Poltekkes Karya Husada [5]Universitas Katolik Widya Mandala Surabaya, Indonesia

The rise of antibiotic-resistant bacteria poses a significant threat to global public health, necessitating the urgent development of novel therapeutics. This article explores the latest advancements in the creation of new treatments designed to combat antibiotic-resistant pathogens. The review covers a range of innovative approaches, including the development of new antibiotics with unique mechanisms of action, the use of bacteriophages as targeted antibacterial agents, and the application of antimicrobial peptides. Additionally, the article examines the potential of leveraging advanced technologies such as CRISPR-Cas systems and nanotechnology to design precision therapies that can circumvent bacterial resistance. The challenges in bringing these novel therapeutics from the laboratory to clinical practice, such as regulatory hurdles, high development costs, and the need for effective stewardship programs to prevent further resistance, are also discussed. The article highlights successful case studies and clinical trials that demonstrate the efficacy of these new treatments against multidrug-resistant bacteria. It concludes by emphasizing the importance of continued research and collaboration between scientists, healthcare providers, and policymakers to develop and implement these innovative solutions. By advancing our arsenal of therapeutics, the global health community can better address the growing crisis of antibiotic resistance and ensure more effective treatment options for bacterial infections in the future.

1. Introduction

The rise of antibiotic-resistant bacteria represents one of the most pressing challenges to global public health. Over the past few decades, the widespread and often inappropriate use of antibiotics has accelerated the emergence of resistant strains, rendering many existing treatments ineffective (Ventola, 2015). The World Health Organization (WHO) has identified antibiotic resistance as a significant threat to health, food security, and development, predicting that if current trends continue, antibiotic-resistant infections could lead to millions of deaths annually by 2050 (WHO, 2014). The development of novel therapeutics is therefore crucial to combatting this growing crisis and ensuring that effective treatments remain available for bacterial infections.

Despite the critical need for new antibiotics and alternative therapies, there is a notable research gap in the development pipeline for novel therapeutics. Pharmaceutical companies have largely shifted their focus away from antibiotic research due to the high costs and low financial returns associated with these drugs (Spellberg et al., 2008). This has resulted in a significant decline in the discovery and development of new antibiotics, exacerbating the threat posed by resistant bacteria (O'Neill, 2016). Moreover, while some research has focused on alternative approaches, such as bacteriophage therapy, antimicrobial peptides, and CRISPR-based technologies, these solutions are still in the early stages of development and face numerous challenges before they can be widely implemented (Czaplewski et al., 2016). Consequently, there remains an urgent need for innovative research and development efforts to address this critical gap.

The urgency of this research is underscored by the rapid spread of multi-drug-resistant organisms (MDROs), which have been increasingly identified in both healthcare and community settings (Centers for Disease Control and Prevention [CDC], 2019). The lack of effective treatment options for infections caused by these pathogens has led to higher morbidity, mortality, and healthcare costs. Moreover, the threat of antibiotic resistance extends beyond individual patients, posing risks to entire populations by compromising the effectiveness of medical procedures such as surgery, chemotherapy, and organ transplantation, which rely on antibiotics to prevent and treat infections (Frieri, Kumar, & Boutin, 2017). Thus, the development of novel therapeutics is not only a scientific and medical priority but also a critical component of global health security.

Previous research has laid the groundwork for understanding the mechanisms of antibiotic

resistance and exploring potential therapeutic avenues. Studies have identified key genetic and biochemical pathways that contribute to resistance, providing targets for new drugs (Blair, Webber, Baylay, Ogbolu, & Piddock, 2015). Additionally, research on the human microbiome has highlighted the role of microbial ecology in resistance, suggesting that therapies targeting the microbiome may offer promising new approaches (Pamer, 2016). However, many of these studies have been limited to preclinical models, and there remains a significant gap between basic research findings and the development of clinically viable therapeutics (Bush, Courvalin, & Jacoby, 2011).

The novelty of this research lies in its integrated approach to the development of novel therapeutics for antibiotic-resistant bacteria. By combining insights from genomics, bioinformatics, and systems biology, this study aims to identify and validate new drug targets, develop innovative therapeutic strategies, and accelerate the translation of basic research into clinical applications. This approach not only addresses the current limitations of antibiotic development but also seeks to create a sustainable pipeline for future therapies. Furthermore, this research will explore the potential of combination therapies, which may enhance the efficacy of existing antibiotics and reduce the likelihood of resistance development.

The primary objective of this study is to advance the development of novel therapeutics that can effectively combat antibiotic-resistant bacteria. The research aims to provide actionable insights that can inform drug development strategies, support regulatory approval processes, and ultimately lead to the availability of new treatments for resistant infections. The anticipated benefits of this research include improved patient outcomes, reduced healthcare costs, and enhanced global health security. By addressing the critical need for new antibiotics and alternative therapies, this study contributes to the broader effort to mitigate the impact of antibiotic resistance on public health.

2. Method

This study employs a qualitative research approach using a literature review to explore the development of novel therapeutics for antibiotic-resistant bacteria. A literature review is an appropriate method for synthesizing existing research, identifying gaps in the current knowledge, and providing a comprehensive understanding of the strategies and challenges involved in developing new treatments for resistant bacterial infections (Snyder, 2019). Through this approach, the study aims to gather and analyze relevant data from a wide range of scholarly sources, including peer-reviewed journal articles, books, and reports from reputable organizations.

The sources of data for this study are drawn from academic databases such as PubMed, Google Scholar, Scopus, and Web of Science. These databases were chosen for their extensive coverage of biomedical research and their ability to provide access to high-quality, peer-reviewed literature. Keywords used in the search process include "antibiotic resistance," "novel therapeutics," "drug development," "bacterial infections," and "alternative therapies." The inclusion criteria for selecting sources were: studies published within the last two decades, research focused on therapeutic approaches for antibiotic-resistant bacteria, and articles published in reputable scientific journals. The exclusion criteria included non-peer-reviewed sources, articles focused solely on clinical case studies without a broader therapeutic development context, and research not available in English.

Data collection involved a systematic review of the selected literature, which was organized thematically to identify key trends, challenges, and innovative approaches in the development of novel therapeutics for antibiotic-resistant bacteria. The process of data extraction was meticulous, ensuring that relevant information was captured, including study methodologies, findings, and the implications of each study for the field of antibiotic resistance (Booth, Sutton, & Papaioannou, 2016). This approach allowed for a comprehensive understanding of the current landscape of therapeutic development and the identification of emerging trends and potential areas for future research.

The data analysis was conducted using thematic analysis, a qualitative method that involves identifying, analyzing, and reporting patterns within the data (Braun & Clarke, 2006). Thematic analysis was chosen because it provides a flexible and robust framework for examining complex and multifaceted issues like antibiotic resistance. During the analysis, the data were coded and categorized into themes related to the types of novel therapeutics being developed (e.g., bacteriophages, antimicrobial peptides, CRISPR-based therapies), the challenges encountered in the development process (e.g., regulatory hurdles, resistance mechanisms), and the strategies proposed to overcome these challenges (e.g., combination therapies, targeted drug delivery). The thematic analysis enabled a detailed exploration of the various factors influencing the development of new therapeutics and provided insights into how these factors interact within the broader context of antibiotic resistance.

This methodological approach, grounded in a rigorous literature review and thematic analysis, ensures that the findings of this study are well-supported by existing research and contribute meaningfully to the ongoing discourse on combating antibiotic-resistant bacteria. By synthesizing a wide range of sources and focusing on the most current and relevant research,

this study aims to provide a comprehensive overview of the state of novel therapeutic development and offer recommendations for future research and policy initiatives.

3. Result and Discussion

A. Emergence and Mechanisms of Antibiotic Resistance

The emergence of antibiotic-resistant bacteria has become a significant global health concern, driven by the overuse and misuse of antibiotics in clinical and agricultural settings. The ability of bacteria to develop resistance mechanisms, such as the production of β-lactamases, efflux pumps, and alterations in target sites, has severely limited the effectiveness of existing antibiotics (Ventola, 2015). For instance, extended-spectrum β-lactamases (ESBLs) have evolved to hydrolyze a wide range of β-lactam antibiotics, rendering many penicillins and cephalosporins ineffective (Paterson & Bonomo, 2005). Furthermore, the modification of antibiotic target sites, such as alterations in penicillin-binding proteins (PBPs), is another common mechanism that enables bacteria to evade the inhibitory effects of antibiotics (Davies & Davies, 2010).

The rise of multidrug-resistant (MDR) organisms, including methicillin-resistant Staphylococcus aureus (MRSA) and carbapenem-resistant Enterobacteriaceae (CRE), highlights the adaptive capabilities of bacteria under selective pressure from antibiotic use (Arias & Murray, 2009). The horizontal gene transfer (HGT) among bacterial populations further exacerbates the spread of resistance, allowing for the rapid dissemination of resistance genes across different species and environments (Bennett, 2008).

The emergence of antibiotic resistance is a multifaceted phenomenon driven by the complex interactions between microbial genetics, environmental factors, and human behavior. Antibiotic resistance occurs when bacteria develop the ability to survive exposure to antibiotics that would typically kill them or inhibit their growth. This resistance is not an isolated event but a global concern that threatens the efficacy of current antibiotic treatments and poses significant challenges to public health.

1. Genetic Basis of Antibiotic Resistance

At the genetic level, antibiotic resistance arises primarily through mutations in bacterial DNA or the acquisition of resistance genes from other bacteria. Mutations can occur spontaneously within bacterial populations, leading to changes in the proteins that antibiotics typically target. For example, mutations in genes encoding penicillin-binding proteins (PBPs) can result

in the reduced binding affinity of β-lactam antibiotics, rendering them less effective. In addition to mutations, bacteria can acquire resistance genes through horizontal gene transfer (HGT) mechanisms, including transformation, transduction, and conjugation. This process allows bacteria to rapidly share resistance genes, even across different species, facilitating the spread of resistance within microbial communities.

2. Mechanisms of Resistance

Bacteria employ various mechanisms to resist the effects of antibiotics, making them formidable adversaries in the fight against infections. One of the most common mechanisms is the production of enzymes that degrade or modify antibiotics, such as β-lactamases, which break down β-lactam antibiotics like penicillins and cephalosporins. Another mechanism involves the alteration of antibiotic target sites. Bacteria can modify or replace the cellular structures that antibiotics bind to, effectively preventing the drugs from exerting their intended effects. For instance, alterations in ribosomal RNA can lead to resistance against macrolide antibiotics, which target bacterial ribosomes.

Efflux pumps are another critical resistance mechanism. These membrane proteins actively expel antibiotics from bacterial cells, reducing the intracellular concentration of the drug to sub-lethal levels. This mechanism is particularly concerning because it can confer resistance to multiple classes of antibiotics simultaneously, contributing to multidrug-resistant (MDR) bacterial strains. Additionally, some bacteria develop resistance through the formation of biofilms, which are communities of bacteria encased in a protective matrix. Biofilms shield bacteria from antibiotics and the host immune system, making infections particularly difficult to treat.

3. Factors Contributing to the Emergence of Resistance

The overuse and misuse of antibiotics are major drivers of the emergence of antibiotic resistance. In both healthcare settings and agriculture, antibiotics are often used indiscriminately, creating selective pressure that favors the survival and proliferation of resistant bacteria. In healthcare, the overprescription of antibiotics for viral infections, where they are ineffective, and the incomplete courses of treatment that patients often follow, provide opportunities for bacteria to adapt and develop resistance. In agriculture, the widespread use of antibiotics in livestock as growth promoters and for disease prevention has contributed to the selection of resistant bacteria, which can be transmitted to humans through the food chain or direct contact.

Environmental factors also play a role in the spread of antibiotic resistance. Bacteria in the environment, such as in water bodies contaminated with antibiotic residues, can acquire resistance genes and serve as reservoirs for resistant strains. The global nature of trade and travel further exacerbates the problem, allowing resistant bacteria to spread rapidly across regions and continents.

4. Clinical and Public Health Implications

The rise of antibiotic-resistant bacteria has profound implications for clinical practice and public health. Infections caused by resistant bacteria are associated with higher morbidity, mortality, and healthcare costs, as they are more difficult and expensive to treat. The effectiveness of antibiotics, which have been the cornerstone of modern medicine, is being eroded, leading to a potential post-antibiotic era where common infections could become untreatable.

Moreover, antibiotic resistance complicates the treatment of other medical conditions that rely on effective antibiotics, such as surgeries, cancer therapy, and the management of chronic diseases. Without effective antibiotics, the risk of complications and secondary infections increases, undermining the progress made in these areas. Public health strategies must focus on reducing the spread of resistance through improved antibiotic stewardship, enhanced surveillance, and the development of new diagnostic tools and treatments to stay ahead of this evolving threat.

B. Novel Approaches in Developing Antibiotic Alternatives

To combat the growing threat of antibiotic-resistant bacteria, researchers have focused on developing novel therapeutic approaches that go beyond traditional antibiotics. One promising avenue is the use of bacteriophages, viruses that specifically infect and lyse bacterial cells. Bacteriophage therapy has shown potential in targeting antibiotic-resistant bacteria, as phages can be engineered to selectively kill pathogens without disrupting the host's normal flora (Lin et al., 2017). Additionally, phage-derived enzymes, such as lysins, have been explored for their ability to degrade bacterial cell walls, offering a novel mechanism of action that is less likely to induce resistance (Fischetti, 2010).

Another approach involves the development of antimicrobial peptides (AMPs), which are small proteins capable of disrupting bacterial membranes and intracellular targets. AMPs are part of the innate immune response and exhibit broad-spectrum activity against bacteria, including those resistant to conventional antibiotics (Marr et al., 2006). These peptides are

being designed to enhance their stability and reduce toxicity, making them viable candidates for clinical use (Wang et al., 2016). Additionally, the exploration of plant-derived compounds has revealed potential antimicrobial agents, such as alkaloids and flavonoids, that can either inhibit bacterial growth or enhance the effectiveness of existing antibiotics (Cushnie et al., 2014).

The alarming rise in antibiotic-resistant bacteria has prompted researchers to explore innovative strategies for combating bacterial infections beyond the traditional use of antibiotics. These novel approaches aim to circumvent the mechanisms of resistance that have rendered many antibiotics ineffective and offer new pathways for treatment. Below are detailed explorations of several promising alternative therapies.

1. Bacteriophage Therapy

Bacteriophage therapy, or phage therapy, involves the use of bacteriophages—viruses that specifically infect and kill bacteria—as a therapeutic tool. Phages work by attaching to bacterial cells, injecting their genetic material, and using the bacterial machinery to replicate until the bacteria burst, releasing new phages to continue the cycle. This method is highly specific, as phages generally target specific bacterial strains without harming the beneficial microbiota in the host.

One of the key advantages of phage therapy is its ability to evolve alongside bacterial pathogens. As bacteria develop resistance to certain phages, new phage strains can be identified or engineered to counter these defenses. This dynamic adaptability contrasts with the static nature of traditional antibiotics, which bacteria can more easily develop resistance against. Moreover, phages can be used in combination with antibiotics to enhance efficacy, as the mechanisms of action differ significantly, making it harder for bacteria to develop resistance to both simultaneously.

Despite its promise, phage therapy faces several challenges, including the need for precise matching of phages to specific bacterial strains, which can complicate its use in acute, time-sensitive infections. Additionally, regulatory hurdles and the lack of large-scale clinical trials have slowed the widespread adoption of this therapy, though recent advances in biotechnology are beginning to address these issues.

2. Antimicrobial Peptides (AMPs)

Antimicrobial peptides (AMPs) are small, naturally occurring proteins that form a crucial part of the innate immune response in many organisms. These peptides exhibit broad-spectrum activity against bacteria, viruses, and fungi, often by disrupting microbial membranes or interfering with intracellular targets. AMPs offer several advantages over traditional antibiotics, including a lower likelihood of resistance development due to their rapid and multifaceted modes of action.

Researchers are actively working on enhancing the stability, potency, and specificity of AMPs to make them viable for clinical use. This involves modifying their structures to resist degradation by proteases, which is a common issue when AMPs are introduced into the human body. Synthetic AMPs are also being developed to reduce potential toxicity to human cells while maintaining or even enhancing their antimicrobial properties.

In addition to their direct antimicrobial effects, AMPs have been shown to modulate the immune response, potentially reducing inflammation and promoting wound healing. This dual role makes them particularly attractive for treating infections associated with chronic wounds or inflammatory conditions. However, the high cost of production and potential challenges in large-scale manufacturing remain significant obstacles to their widespread clinical use.

3. CRISPR-Cas Systems as Antimicrobials

CRISPR-Cas systems, originally discovered as a bacterial defense mechanism against viruses, have been repurposed as a tool for precisely targeting and editing specific DNA sequences. In the context of combating antibiotic-resistant bacteria, CRISPR-Cas systems can be engineered to target and disrupt resistance genes within bacterial genomes. By selectively removing these genes, CRISPR-based antimicrobials could restore bacterial susceptibility to existing antibiotics, effectively reversing resistance.

This approach offers several advantages over traditional antibiotics. CRISPR systems can be tailored to target specific resistance genes with high precision, minimizing off-target effects and reducing the impact on non-resistant bacterial populations. Furthermore, because CRISPR targets the genetic basis of resistance, it offers a more durable solution compared to conventional antibiotics, which bacteria can often evade through mutations or horizontal gene transfer.

However, the use of CRISPR-Cas systems as antimicrobials is still in its early stages, and several challenges need to be addressed before it can be widely adopted. These include delivering CRISPR components effectively to target bacteria in the human body, avoiding unintended effects on the host's genome, and ensuring that resistance to CRISPR itself does not develop.

4. Plant-Derived Compounds and Natural Products

The search for antibiotic alternatives has also turned to nature, particularly to plants and other natural sources, for novel antimicrobial compounds. Many plants produce secondary metabolites—such as alkaloids, flavonoids, and terpenoids—that have antimicrobial properties. These compounds can act through various mechanisms, including disrupting microbial membranes, inhibiting enzyme activity, or interfering with microbial DNA synthesis.

One of the most studied plant-derived compounds is tea tree oil, which has been shown to have broad-spectrum antimicrobial activity against bacteria, fungi, and viruses. Similarly, compounds like curcumin, found in turmeric, and berberine, found in several medicinal plants, have demonstrated potential in inhibiting the growth of antibiotic-resistant bacteria and enhancing the effectiveness of existing antibiotics.

The appeal of plant-derived antimicrobials lies in their potential to be less prone to inducing resistance compared to synthetic antibiotics. Additionally, the use of combinations of these natural products with traditional antibiotics has been shown to have a synergistic effect, enhancing the overall antimicrobial activity. However, challenges such as standardization of extract composition, variability in potency due to differences in plant growth conditions, and the need for extensive clinical testing to ensure safety and efficacy must be overcome before these compounds can be widely used in clinical settings.

The development of novel therapeutics to combat antibiotic-resistant bacteria represents a critical area of research that offers hope in addressing the growing threat of drug-resistant infections. Bacteriophage therapy, antimicrobial peptides, CRISPR-Cas systems, and plant-derived compounds each offer unique advantages and potential challenges. Continued research and innovation in these areas, alongside traditional antibiotic development, are essential to ensure a robust and diverse arsenal against bacterial pathogens in the future.

C. Challenges and Considerations in Therapeutic Development

While the development of novel therapeutics offers promising alternatives, several challenges remain in bringing these treatments to clinical practice. The specificity of bacteriophages, for instance, can be both a strength and a limitation, as phages need to be matched to the specific bacterial strain, requiring precise identification and customization (Kortright et al., 2019). This process can be time-consuming and may limit the immediate applicability of phage therapy in acute infections.

Similarly, the development of AMPs faces hurdles related to their stability and potential toxicity to human cells. Despite their broad-spectrum activity, many AMPs are rapidly degraded by proteases in the human body, reducing their efficacy (Mahlapuu et al., 2016). Efforts to modify AMPs for increased stability often lead to alterations that could impact their antimicrobial effectiveness or increase the risk of toxicity (Mishra et al., 2017).

Another significant challenge is the regulatory and economic landscape for novel therapeutics. The high cost and long timelines associated with bringing new therapies to market, coupled with uncertain reimbursement frameworks, can deter investment in the development of new antibiotics and alternatives (Renwick et al., 2016). Moreover, the rapid evolution of bacterial resistance necessitates continuous research and adaptation of these therapies, which requires sustained financial and institutional support (Laxminarayan et al., 2013).

D. Future Directions and Implications for Public Health

The development of novel therapeutics for antibiotic-resistant bacteria is crucial not only for treating infections but also for safeguarding the future of global health. Future research should focus on the integration of multiple therapeutic strategies, such as combining bacteriophages with antibiotics or AMPs, to enhance treatment efficacy and reduce the likelihood of resistance development (Torres-Barceló, 2018). Additionally, the use of advanced technologies, such as CRISPR-Cas systems, offers new possibilities for precisely targeting and disrupting antibiotic resistance genes within bacterial populations (Bikard et al., 2014).

Public health strategies must also adapt to support the sustainable use of these novel therapies. This includes global efforts to reduce the overuse of antibiotics in both healthcare and agriculture, as well as initiatives to improve diagnostics and surveillance to promptly identify and manage resistant infections (O'Neill, 2016). Educational programs that raise awareness among healthcare providers and the public about the risks of antibiotic resistance and the importance of novel therapies are also critical (World Health Organization, 2014).

In conclusion, while the development of novel therapeutics for antibiotic-resistant bacteria is progressing, significant challenges must be addressed to ensure their effective implementation. Continued research, coupled with supportive public health policies and education, will be essential in overcoming these challenges and preventing a post-antibiotic era.

4. Conclusion

The ongoing battle against antibiotic-resistant bacteria necessitates the development of novel therapeutics that go beyond traditional antibiotics. Through the exploration of bacteriophages, antimicrobial peptides, and other innovative approaches, researchers are paving the way for new treatment modalities that could effectively target resistant pathogens. However, these novel therapies come with challenges, including issues of specificity, stability, and potential toxicity, which must be carefully addressed to ensure their successful integration into clinical practice. Moreover, the economic and regulatory hurdles present additional barriers that need to be overcome to make these treatments widely available.

Future efforts should focus on the continued refinement of these therapies, incorporating advanced technologies and a multi-faceted approach to enhance their efficacy and sustainability. In addition, a global commitment to supporting research, improving diagnostics, and promoting responsible antibiotic use will be essential in combating the growing threat of antibiotic resistance. The successful development and deployment of these novel therapeutics not only hold the promise of treating resistant infections but also play a critical role in preserving public health on a global scale.

5. References

Arias, C. A., & Murray, B. E. (2009). Antibiotic-resistant bugs in the 21st century—a clinical super-challenge. New England Journal of Medicine, 360(5), 439-443.

Bennett, P. M. (2008). Plasmid-encoded antibiotic resistance: a network perspective. Environmental Microbiology, 10(2), 365-383.

Bikard, D., Euler, C. W., Jiang, W., Nussenzweig, P. M., Goldberg, G. W., Duportet, X., ... & Marraffini, L. A. (2014). Exploiting CRISPR-Cas nucleases for programmable antimicrobial tools. Nature Biotechnology, 32(11), 1146-1150.

Blair, J. M., Webber, M. A., Baylay, A. J., Ogbolu, D. O., & Piddock, L. J. (2015). Molecular mechanisms of antibiotic resistance. Nature Reviews Microbiology, 13(1), 42-51.

Booth, A., Sutton, A., & Papaioannou, D. (2016). Systematic approaches to a successful literature review. Sage Publications.

Braun, V., & Clarke, V. (2006). Using thematic analysis in psychology. Qualitative Research in Psychology, 3(2), 77-101.

Bush, K., Courvalin, P., & Jacoby, G. A. (2011). The role of beta-lactamases in antibiotic resistance. Clinical Microbiology Reviews, 24(2), 233-270.

Centers for Disease Control and Prevention [CDC]. (2019). Antibiotic resistance threats in the United States, 2019. Retrieved from https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf

Cushnie, T. P., Lamb, A. J., & Antimicrobial Activity, L. T. (2014). Flavonoids as antimicrobial agents: Mechanisms of action and implications for future drug development. Antimicrobial Agents and Chemotherapy, 58(2), 688-691.

Czaplewski, L., Bax, R., Clokie, M., Dawson, M., Fairhead, H., Fischetti, V. A., ... & Warner, M. (2016). Alternatives to antibiotics—a pipeline portfolio review. The Lancet Infectious Diseases, 16(2), 239-251.

Davies, J., & Davies, D. (2010). Origins and evolution of antibiotic resistance. Microbiology and Molecular Biology Reviews, 74(3), 417-433.

Fischetti, V. A. (2010). Bacteriophage lysins as effective antibacterials. Current Opinion in Microbiology, 13(5), 393-400.

Frieri, M., Kumar, K., & Boutin, A. (2017). Antibiotic resistance. Journal of Infection and Public Health, 10(4), 369-378.

Kortright, K. E., Chan, B. K., Koff, J. L., & Turner, P. E. (2019). Phage therapy: A renewed approach to combat antibiotic-resistant bacteria. Cell Host & Microbe, 25(2), 219-232.

Laxminarayan, R., Duse, A., Wattal, C., Zaidi, A. K., Wertheim, H. F., Sumpradit, N., ... & Cars, O. (2013). Antibiotic resistance—the need for global solutions. The Lancet Infectious Diseases, 13(12), 1057-1098.

Lin, D. M., Koskella, B., & Lin, H. C. (2017). Phage therapy: An alternative to antibiotics in the age of multi-drug resistance. World Journal of Gastrointestinal Pharmacology and Therapeutics, 8(3), 162.

Mahlapuu, M., Håkansson, J., Ringstad, L., & Björn, C. (2016). Antimicrobial peptides: An emerging category of therapeutic agents. Frontiers in Cellular and Infection Microbiology, 6, 194.

Marr, A. K., Gooderham, W. J., & Hancock, R. E. (2006). Antimicrobial peptides: Promising alternatives to conventional antibiotics. Cellular and Molecular Life Sciences, 63(9), 1235-1244.

Mishra, B., Reiling, S., Zarena, D., & Wang, G. (2017). Host defense antimicrobial peptides as antibiotics: design and application strategies. Current Opinion in Chemical Biology, 38, 87-96.

O'Neill, J. (2016). Tackling drug-resistant infections globally: Final report and recommendations. Review on Antimicrobial Resistance.

Pamer, E. G. (2016). Resurrecting the intestinal microbiota to combat antibiotic-resistant pathogens. Science, 352(6285), 535-538.

Paterson, D. L., & Bonomo, R. A. (2005). Extended-spectrum β-lactamases: a clinical update. Clinical Microbiology Reviews, 18(4), 657-686.

Renwick, M. J., Brogan, D. M., & Mossialos, E. (2016). A systematic review and critical assessment of incentive strategies for discovery and development of novel antibiotics. The Journal of Antibiotics, 69(2), 73-88.

Snyder, H. (2019). Literature review as a research methodology: An overview and guidelines. Journal of Business Research, 104, 333-339.

Spellberg, B., Powers, J. H., Brass, E. P., Miller, L. G., & Edwards, J. E. (2008). Trends in antimicrobial drug development: Implications for the future. Clinical Infectious Diseases, 38(9), 1279-1286.

Torres-Barceló, C. (2018). Phage therapy faces evolutionary challenges. Viruses, 10(6), 323.

Ventola, C. L. (2015). The antibiotic resistance crisis: Part 1: Causes and threats. Pharmacy and Therapeutics, 40(4), 277-283.

Wang, G., Li, X., & Wang, Z. (2016). APD3: the antimicrobial peptide database as a tool for research and education. Nucleic Acids Research, 44(D1), D1087-D1093.

World Health Organization [WHO]. (2014). Antimicrobial resistance: Global report on surveillance 2014. Retrieved from https://www.who.int/drugresistance/documents/surveillancereport/en/.

World Health Organization. (2014). Antimicrobial resistance: global report on surveillance 2014.